Novavax Global Commercial Operations and COVID-19 Vaccine Update
Q4 and FY2022 Financial results
($ in millions, except per share amounts)
Product sales
Grants
Royalties & other
Q4 2022
Q4 2021
FY2022
FY2021
$
288 $
$
1,555 $
70
95
383
949
0
127
44
198
Total revenue
357
222
1,982
1,146
Cost of sales
Research & development
Selling, general & administrative
Total expenses
Income (loss) from operations
Interest expense
Other income (expense)
Income (loss) before income tax expense
Income tax expense (benefit)
182
903
258
963
1,235
2,535
162
84
489
298
601
1,047
2,627
2,833
(244)
(825)
(645)
(1,687)
(5)
(5)
(20)
(21)
64
0
11
(7)
(185)
(830)
(654)
(1,715)
(2)
17
4
29
Net income (loss)
St
$
(182) $
(846)
$
(658) $
(1,744)
Basic net income (loss) per share
$
(2.28) $
(11.18)
AA
$
Basic weighted average common shares outstanding
80
76
(8.42) $
78
(23.44)
74
novavax
© 2023 NOVAVAX. All rights reserved.
22View entire presentation